Identify
We map AI opportunities across your R&D pipeline, from target identification and lead optimization to biomarker discovery and clinical trial design.
Stop guessing about AI. Start with the science.
TranslAItion Partners helps biotech and pharma leaders evaluate, select and implement AI solutions independently, backed by 20+ years of life-science expertise.
- No vendor affiliations
- No referral fees
- No conflicts of interest
The AI Evaluation Gap
Every vendor claims their AI is validated. Who independently checks?
Your team is evaluating AI for target identification, biomarker discovery or clinical optimization. Every vendor claims their platform is scientifically validated. But who independently assesses whether the science holds and whether it fits your pipeline?
- AI platforms for drug discovery, protein structure prediction and multi-omics analysis: too many to compare with confidence
- Uncertainty about scientific reliability, data requirements, integration readiness and true ROI
- Risk of investing in solutions that look promising in a demo but don't hold up in your R&D environment
How It Works
From scientific question to validated decision, and beyond.
We bring scientific judgment and independent evaluation to every AI decision, so you invest in solutions that produce measurable outcomes, not vendor promises.
Evaluate
We compare AI platforms, vendors and scientific claims through an independent lens, including validation of published results, data requirements and integration readiness.
Validate
We design and monitor AI pilots with clear go/no-go criteria, so you evaluate real scientific output, not vendor demos.
Monitor
After implementation, we keep you informed with quarterly intelligence on AI developments, emerging vendors, and shifts relevant to your therapeutic areas and pipeline stage.
Services
Independent AI evaluation tailored to your pipeline and therapeutic areas
Assess
AI Opportunity Assessment
A strategic scan of AI opportunities across your R&D pipeline: target identification, lead optimization, biomarker discovery, clinical trial design and patient stratification.
Deliverable: Prioritized opportunity map + decision framework
Compare
Solution Dossier
Independent evaluation of AI platforms for drug discovery, protein structure prediction, multi-omics analysis or patient stratification, including scientific validation of claims, data requirements and integration readiness.
Deliverable: Comparison report with go/no-go recommendation
Pilot
Pilot Orchestration
We design and monitor AI pilots with clear success criteria, so you evaluate real scientific output against your therapeutic objectives, not vendor demonstrations.
Deliverable: Pilot protocol + success criteria + evaluation report
Monitor
Quarterly Intelligence
Quarterly briefings on AI developments relevant to your therapeutic areas, pipeline stage and competitive landscape, curated not comprehensive.
Deliverable: Quarterly briefing + curated vendor and technology updates
Cost-to-Outcome Intelligence™
From AI cost to scientific outcome
AI solutions are evaluated not on technology hype or price alone, but on their contribution to concrete scientific and organizational outcomes. Every recommendation is grounded in this five-dimensional framework
Scientific Output
Does the solution produce scientifically sound results that hold up under independent review, not just in a demo, but in your therapeutic context?
Time-to-Insight
How much faster does it get your team from data to decision, accounting for setup time, training curves, and integration overhead?
Cost Efficiency
What is the true total cost (licenses, infrastructure, data preparation, team time, and hidden dependencies), mapped against expected value?
Scalability
Can the solution grow with your pipeline, data volumes, and therapeutic areas, or will you hit a ceiling?
Adoption Friction
Will your team actually use it? The most powerful AI produces zero value if it doesn't get adopted.
Why TranslAItion Partners
Not another AI vendor. An independent evaluation partner.
Scientific depth
20+ years of life-science expertise in immunology, oncology and translational medicine. We evaluate AI through a scientific lens, grounded in rigorous research standards.
Vendor independence
No vendor affiliations, no referral fees, no conflicts of interest. Recommendations are based on evidence, fit and expected value alone.
Adoption focus
Decisions are connected to implementation realities, team adoption and long-term value, because an AI solution that isn't adopted produces zero scientific output.
What we are not
- Not a consultancy: we don't sell implementation projects or bill for hours; we evaluate and advise.
- Not a vendor: we don't build AI platforms or resell software; we assess them independently.
- Not a broker: we don't earn referral fees or commissions; our only incentive is your scientific outcome.
Principal
Dr. Rogier Reijmers
Immunologist · Translational Scientist · AI Evaluation Advisor
"After more than two decades in life sciences, I've seen too many organizations invest in new technologies that looked promising in a demo but didn't hold up in a real R&D environment. TranslAItion Partners exists to change that."
- PhD in Immunology with 20+ years of experience in translational research in both academic and industry environments
- Background at multiple Medical Centers in Amsterdam (VUmc, AMC), Rotterdam (ErasmusMC) and Leiden (LUMC)
- Established cross-continental collaborations
- Published researcher in immunology, oncology and translational medicine
- Deep experience in grant review, scientific due diligence, and technology evaluation
- Based in Aalsmeer, serving biotech and pharma across Europe and beyond
For Whom
Built for leaders making AI adoption decisions in life sciences
Decision makers
- Chief Scientific Officers
- VPs of Discovery
- Innovation Leads
- Translational Science Leaders
- Drug Discovery Leaders
Organizations
- Biotech scale-ups and mid-sized biotech companies
- Pharmaceutical innovation teams and R&D leaders
- Organizations evaluating AI for their R&D pipeline
Ready to make better AI decisions?
Let's explore where AI can create measurable scientific value for your pipeline.
All conversations are confidential. We respond within 24 hours.